RECURRENT SUPRAVENTRICULAR TACHYCARDIA ASSOCIATED WITH LAPATINIB: A CASE REPORT OF A PROBABLE CARDIAC ADVERSE EFFECT
PDF
Cite
Share
Request
Case Report
P: 188-190
July 2011

RECURRENT SUPRAVENTRICULAR TACHYCARDIA ASSOCIATED WITH LAPATINIB: A CASE REPORT OF A PROBABLE CARDIAC ADVERSE EFFECT

Eur J Breast Health 2011;7(3):188-190
1. Adnan Menderes University Faculty of Medicine, Division of Medical Oncology, Aydın, Turkey
No information available.
No information available
Received Date: 01.07.2010
Accepted Date: 06.12.2010
PDF
Cite
Share
Request

ABSTRACT

While cardiac toxicity due to chemotherapeutic agents is rare, it is a major cause of mortality. The most frequent cardiac toxicity is myocardial cell damage and particularly left ventricular ejection fraction reduction, which is due to anthracycline, progresses irreversibly to cardiac failure. However in trastuzumab associated cardiotoxicity, contractility dysfunction occurs in myocytes and the reduction of ejection fraction is reversible, since there is no cell damage. This cardiotoxicity which is due to transtuzumab is quite rare and although more rarely, it may also develop in patients using lapatinib through a similar mechanism. Nevertheless, cardiac arrhythmia without a left ventricular dysfunction is not reported in the literature. In this article, we aimed to present an electrocardiography confirmed supraventicular tachycardia attack which had developed after the first dose of lapatinib in a metastatic breast cancer patient. We want to discuss the development of an isolated supraventricular tachycardia, without a left ventricular dysfunction, in patients who do not have a history of hypertension, cardiac disease or any sign of cardiotoxicity, through using the cardiotoxicity related information in the literature.

Keywords:
lapatinib, trastuzumab, antiHer2 treatment, cardiotoxicity, arrhythmia, tyrosine kinase inhibitors